ReviewBJR open2025
Exploring the therapeutic potential of localized alpha irradiation for cancer: from DNA damage to immune activation.
Review in BJR open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Scoping Review of the Challenges and Future Perspectives in the Use of Alpha-Emitters for Metastatic Ovarian Cancer.Molecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alpha radiation has emerged as a promising modality in cancer treatment due to its unique physical and biological properties. Among these, diffusing alpha-emitters radiation therapy (DaRT) delivers alpha radiation directly into solid tumours using inserted seeds. This review synthesizes both the biological mechanisms and therapeutic implications of alpha irradiation, with a focus on DaRT. We explore how alpha particles induce complex DNA damage, modulate the tumour microenvironment, and interact with immune therapies. Emphasis is placed on preclinical and early clinical findings that suggest DaRT's potential to improve outcomes, especially in difficult-to-treat malignancies. The high linear energy transfer (LET) radiation induces complex DNA damage in tumour cells, leading to increased cell death compared to conventional radiotherapy. Alpha particles have a short range in tissue, allowing for highly localized treatment with minimal damage to surrounding healthy tissue. Recent studies have demonstrated that alpha radiation can stimulate antitumor immune responses, potentially enhancing treatment efficacy. Clinical trials utilizing alpha-emitting radioisotopes have shown encouraging results in various cancer types, particularly for metastatic disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.